2-bicyclo[2.2.1]hept-2-yl-5-nitro-1H-isoindole-1,3(2H)-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-bicyclo[2.2.1]hept-2-yl-5-nitro-1H-isoindole-1,3(2H)-dione
• 英文别名: 2-(2-bicyclo[2.2.1]heptanyl)-5-nitroisoindole-1,3-dione
• 化学式: C15H14N2O4
• 分子量: 286.28
• InChiKey: IKFDTAHCCFDZSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  83.2
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Antiviral Compounds and Methods of Use Thereof
  申请人：Guenther Richard H.

  公开号：US20130071353A1

  公开（公告）日：2013-03-21

  Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.

  本文披露了逆转录病毒传播的抑制剂、使用这些抑制剂进行逆转录病毒感染的治疗和预防方法，以及包括这些抑制剂的制药组合物。
• Antiviral compounds and methods of use thereof
  申请人：Trana Discovery, Inc.

  公开号：US10098887B2

  公开（公告）日：2018-10-16

  Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.

  本研究公开了逆转录病毒传播抑制剂、使用这些抑制剂治疗和预防逆转录病毒感染的方法以及包括这些抑制剂的药物组合物。
• ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Trana Discovery, Inc.

  公开号：US20160129006A1

  公开（公告）日：2016-05-12

  Inhibitors of retroviral propagation, methods of treatment and prevention of retroviral infections using the inhibitors, and pharmaceutical compositions including the inhibitors, are disclosed.
• US9173886B2
  申请人：——

  公开号：US9173886B2

  公开（公告）日：2015-11-03
• [EN] COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT D'INFECTIONS RÉTROVIRALES PHARMACORÉSISTANTES
  申请人：TRANA DISCOVERY INC

  公开号：WO2012079032A2

  公开（公告）日：2012-06-14

  Methods of treating drug-resistant retroviral infections, such as those caused by drug- resistant HIV-I, HIV-II, and HIV-III, are disclosed. The methods involve administering a compound that is an inhibitor of retroviral propagation. The inhibitors inhibits the ability of any portion of the HIV genome involved in reverse transcription to bind to or associate with a host cell tRNA, or the inhibitor disrupts the RNA/RNA complex formed between the viral genome and the human tRNA primer, or the binding or association of the host cell tRNA to a retroviral genome initiates, primes, or facilitates reverse transcription of the retroviral genome in the absence of the administered compound.